Hans Lee, MD, on the LINKER-MM1 Study of Linvoseltamab in Multiple Myeloma

Hans Lee, MD, of the University of Texas MD Anderson Cancer Center, discusses his 2023 American Society of Clinical Oncology Annual Meeting presentation on linvoseltamab in patients with relapsed or refractory multiple myeloma.

Dr. Lee and colleagues evaluated linvoseltamab, a bispecific antibody targeting BCMA and CD3, in the phase II LINKER-MM1 study. They compared doses of 50 mg and 200 mg in two cohorts of patients with multiple myeloma who progressed after at least three lines of therapy.

In this video, Dr. Lee speaks about the rationale behind the study and its design, as well as its efficacy and safety findings. He also speaks about how the therapy can address unmet needs in this population of patients and what he sees as the next steps with the research.